AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03736694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia
Description: CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).
Study NCT03736694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, \& Daley, 2003).
Study NCT03241056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Maladaptive Beliefs about Memory
Description: The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
Study NCT02276404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation training
Description: The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes.
Study NCT02276404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
Study NCT02163980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caudal ropivacaine + normal saline
Study NCT02163980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine + dexmedetomidine
Study NCT02439879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased >3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
Study NCT03935412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block
Study NCT03935412 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block
Study NCT02140112 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris suis ova
Study NCT02140112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03263585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal orthosis Spinomed
Study NCT03263585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Equipment training
Study NCT05191654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: evaluation of cardiopulmonary parameters, gross motor development and hand grip strength
Description: Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
Study NCT02261610 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procalcitonin algorithm
Description: Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
Study NCT02261610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procalcitonin algorithm
Description: Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
Study NCT06351371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT01417936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
Study NCT02407418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
Study NCT03241056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
Study NCT06351371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02407418 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: A simulated lumbar spine manipulation in which no vertebral contact was made
Study NCT01368432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
Study NCT01368432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill placebo
Study NCT01270542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (bevacizumab)
Description: single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
Study NCT01270542 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Subject's eyes will be anesthetized but no injection will be performed.
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: 100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: 100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study NCT06004934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.
Study NCT06004934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avacopan
Description: Administered orally.
Study NCT01620281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no!no!Back
Description: Self treatments daily for 3 weeks, in up to three 10-minutes sessions
Study NCT01620281 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: no!no!Back
Description: Self treatments daily for 3 weeks, in up to three 10-minutes sessions
Study NCT00438659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: Applied to treatment area
Study NCT00438659 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied to treatment area
Study NCT02987634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PeriActive
Description: mouthwash
Study NCT02987634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PeriActive
Description: mouthwash
Study NCT01022255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous FL vaccine
Description: 1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Description: 600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enticavir
Description: 0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enticavir
Description: 0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Study NCT06351371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06351371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given orally
Study NCT06351371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil Tablets
Description: 10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study NCT00810524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil Tablets
Description: 10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium
Description: Oral inhalation by HandiHaler® device
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Oral inhalation by HandiHaler® device
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salmeterol
Description: Oral inhalation from Diskus®
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Oral inhalation from Diskus®
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Oral inhalation from metered dose inhaler (MDI)
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide low
Description: Oral inhalation from MDI
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide high
Description: Oral inhalation from MDI
Study NCT00535366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation from MDI
Study NCT01598025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT04462510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Block/Local infiltration
Description: One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
Study NCT01598025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT01598025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01598025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT04210583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vulvovaginal Treatment
Description: Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment).
Study NCT04531540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425)
Description: Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
Study NCT00971009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPPC service
Description: Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
Study NCT00971009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebChoice IHCA
Description: The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
Study NCT01225796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate 650mg by mouth three times daily for 6 months.
Study NCT02027038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic belt application
Study NCT01351363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pain threshold measurement
Description: Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
Study NCT01351363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of electrical pain threshold
Description: Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
Study NCT02027038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic belt application
Study NCT01873508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Fast release MR capsule, single dose
Study NCT01873508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Target release MR capsule, single dose
Study NCT01873508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Slow release MR capsule, single dose
Study NCT01873508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: \[13C\]-labeled tracer dose i.v.
Study NCT00896844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotional disclosure
Description: writing about emotional events from the past
Study NCT00629512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg oral daily
Study NCT00629512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral daily
Study NCT00629512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02462655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-lipid apheresis
Description: Blood samples will be taken just before the start of the lipid apheresis treatment.
Study NCT02462655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-lipid apheresis
Description: Blood samples will be taken following the lipid apheresis treatment.
Study NCT03036605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: %0.5 bupivacaine
Study NCT03036605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8 mg Dexamethasone
Study NCT03266523 — intervention group
Intervention type: OTHER
Intervention: Natural images in imaging waiting rooms
Description: Standard environment for hospital imaging waiting rooms
Study NCT00814853 — intervention group
Intervention type: DEVICE
Intervention: NAVA (Extubation readiness testing failures)
Description: Patients who fail the ERT will be place in the mode of ventilation NAVA.
Study NCT02910869 — intervention group
Intervention type: GENETIC
Intervention: Pathway Genomics FIT test
Study NCT04436211 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: The common procedure of Total Knee Arthroplasty is investigated in order to compare the techniques of implantation (kinematic vs mechanical alignment)
Study NCT04185519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI (model)
Description: The process of the experiment (brief describe) This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose. Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl. Once the failed rate by AI is higher than the physician is 5%, , the study will be terminated. There will be three periods, namely ry 3 months.
Study NCT03361592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy
Description: Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
Study NCT03361592 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT).
Study NCT00984282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
Study NCT00984282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
Study NCT04664777 — intervention group
Intervention type: DEVICE
Intervention: Masimo Model RDS7A
Description: Masimo monitoring platform equipped with Radical-7 Pulse CO-Oximeter fingertip probe for measurement non-invazive hemoglobin level (SpHb) an perfusion index (PI)
Study NCT02286440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AssureRx GeneSight genotyping results
Study NCT02286440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study NCT02999282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: 10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
Study NCT00896844 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo writing
Description: writing about how they spent their time the previous day
Study NCT03432273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Nicotine mint lozenge, 2 mg
Study NCT03432273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: NiQuitin mint lozenge, 2 mg
Study NCT02999282 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: 10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
Study NCT02964390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Pulmonary Angioplasty
Study NCT02845791 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interactive Lifestyle programme workshop
Description: Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).